{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:45:16Z","timestamp":1795023916710,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01669-4","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:48:37Z","timestamp":1736311717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Post-marketing safety concerns with lecanemab: a\u00a0pharmacovigilance study based on\u00a0the\u00a0FDA Adverse Event Reporting System database"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiaoxuan","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/bmj.p1580","volume":"382","author":"E Mahase","year":"2023","unstructured":"Mahase E. Alzheimer\u2019s disease: Lecanemab gets full FDA approval and black box safety warning. BMJ. 2023;382:1580. https:\/\/doi.org\/10.1136\/bmj.p1580.","journal-title":"BMJ"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.p73","volume":"380","author":"E Mahase","year":"2023","unstructured":"Mahase E. Alzheimer\u2019s disease: FDA approves lecanemab amid cost and safety concerns. BMJ. 2023;380:73. https:\/\/doi.org\/10.1136\/bmj.p73.","journal-title":"BMJ"},{"issue":"1","key":"1669_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"1669_CR4","doi-asserted-by":"publisher","first-page":"q1692","DOI":"10.1136\/bmj.q1692","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase E. Lecanemab: European drug agency rejects Alzheimer\u2019s drug amid debate over efficacy and safety. BMJ. 2024;386:q1692. https:\/\/doi.org\/10.1136\/bmj.q1692.","journal-title":"BMJ"},{"key":"1669_CR5","doi-asserted-by":"publisher","first-page":"862369","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease. Front Neurol. 2022;13:862369. https:\/\/doi.org\/10.3389\/fneur.2022.862369.","journal-title":"Front Neurol"},{"issue":"5","key":"1669_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/nejmc221514","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B, et al. Multiple cerebral haemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388(5):478\u20139. https:\/\/doi.org\/10.1056\/nejmc221514.","journal-title":"N Engl J Med"},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, et al. Lecanemab, Aducanumab, and Gantenerumab-binding profiles to different forms of amyloid-Beta might explain Efficacy and Side effects in clinical trials for Alzheimer\u2019s Disease. Neurotherapeutics. 2023;20:195\u2013206. https:\/\/doi.org\/10.1007\/s13311-022-01308-6.","journal-title":"Neurotherapeutics"},{"key":"1669_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191. https:\/\/doi.org\/10.1186\/s13195-022-01124-2.","journal-title":"Alzheimers Res Ther"},{"issue":"7\u20138","key":"1669_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357. https:\/\/doi.org\/10.1016\/j.drudis.2008.12.012.","journal-title":"Drug Discov Today"},{"key":"1669_CR11","doi-asserted-by":"crossref","unstructured":"US Food & Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files. Accessed September 25, 2024.","DOI":"10.2174\/0113894501290296240327081624"},{"key":"1669_CR12","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s Adverse Event Reporting System. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed September 25, 2024."},{"key":"1669_CR13","unstructured":"MedDRA. Introductory Guide: MedDRA version 27.1. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_27_1_English.pdf. Published September 2024. Accessed September 25, 2024."},{"key":"1669_CR14","unstructured":"ICH. Harmonisation for better health: MedDRA work products. http:\/\/www.ich.org\/products\/meddra.html. Accessed September 25, 2024."},{"issue":"6","key":"1669_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1669_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28(6):533\u201342. https:\/\/doi.org\/10.1016\/j.numecd.2018.02.014.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"1669_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"10","key":"1669_CR18","doi-asserted-by":"publisher","first-page":"E1512","DOI":"10.7150\/ijms.6048","volume":"10","author":"ND Pace","year":"2018","unstructured":"Pace ND, Multani JK. On the reporting of odds ratios and risk ratios. Nutrients. 2018;10(10):E1512. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Nutrients"},{"issue":"1","key":"1669_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychother Psychosom. 2021;90(1):41\u20138. https:\/\/doi.org\/10.1159\/000510703.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"1669_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1669_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1669_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/pds.4970","volume":"29","author":"L Dijkstra","year":"2020","unstructured":"Dijkstra L, Garling M, Foraita R, Pigeot I. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems. Pharmacoepidemiol Drug Saf. 2020;29(4):396\u2013403. https:\/\/doi.org\/10.1002\/pds.4970.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1669_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1248\/bpb.b15-00243","volume":"38","author":"R Umetsu","year":"2015","unstructured":"Umetsu R, Abe J, Ueda N, et al. Association between selective serotonin reuptake inhibitor therapy and suicidality: Analysis of US Food and Drug Administration Adverse Event Reporting System data. Biol Pharma Bull. 2015;38(11):1689\u201399. https:\/\/doi.org\/10.1248\/bpb.b15-00243.","journal-title":"Biol Pharma Bull."},{"issue":"4","key":"1669_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283\u201394. https:\/\/doi.org\/10.1007\/s40264-014-0150-2.","journal-title":"Drug Saf"},{"key":"1669_CR25","doi-asserted-by":"publisher","first-page":"1196185","DOI":"10.3389\/fnagi.2023.1196185","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim J, Ha WS, Park SH, Han K, Baek MS. Association between migraine and Alzheimer\u2019s disease: a nationwide cohort study. Front Aging Neurosci. 2023;15:1196185. https:\/\/doi.org\/10.3389\/fnagi.2023.1196185.","journal-title":"Front Aging Neurosci"},{"key":"1669_CR26","doi-asserted-by":"publisher","first-page":"1233601","DOI":"10.3389\/fnins.2023.1233601","volume":"17","author":"H Xue","year":"2023","unstructured":"Xue H, Zeng L, Liu S. Unraveling the link: exploring the causal relationship between diabetes, multiple sclerosis, migraine, and Alzheimer\u2019s disease through Mendelian randomization. Front Neurosci. 2023;17:1233601. https:\/\/doi.org\/10.3389\/fnins.2023.1233601.","journal-title":"Front Neurosci"},{"issue":"3","key":"1669_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/14740338.2022.2027905","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y. Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer\u2019s disease: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(3):407\u201315. https:\/\/doi.org\/10.1080\/14740338.2022.2027905.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1669_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","volume":"23","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, et al. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023;23(3):512\u201322. https:\/\/doi.org\/10.1111\/psyg.12944.","journal-title":"Psychogeriatrics"},{"issue":"17","key":"1669_CR29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"GC Alexander","year":"2021","unstructured":"Alexander GC, Emerson S, Kesselheim AS. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. JAMA. 2021;325(17):1717\u20138. https:\/\/doi.org\/10.1001\/jama.2021.3854.","journal-title":"JAMA"},{"key":"1669_CR30","unstructured":"CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer\u2019s Disease. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment. Published April 2022. Accessed December 10, 2024."},{"key":"1669_CR31","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"JC Weber","year":"1984","unstructured":"Weber JC. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. New York: Raven Press; 1984. p. 1\u20137."},{"issue":"4","key":"1669_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2214\/AJR.22.28461","volume":"220","author":"M Roytman","year":"2023","unstructured":"Roytman M, Mashriqi F, Al-Tawil K, et al. Amyloid-Related Imaging Abnormalities: An Update. AJR Am J Roentgenol. 2023;220(4):562\u201374. https:\/\/doi.org\/10.2214\/AJR.22.28461.","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"1669_CR33","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"issue":"2","key":"1669_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alzheimers Dis. 2022;9(2):221\u201330. https:\/\/doi.org\/10.14283\/jpad.2022.34.","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"1669_CR35","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/bjsports-2018-100054","volume":"54","author":"NT Borgen","year":"2020","unstructured":"Borgen NT. Collider bias (aka sample selection bias) in observational studies: why the effects of hyperandrogenism in elite women\u2019s sport are likely underestimated. Br J Sports Med. 2020;54(12):750\u20132. https:\/\/doi.org\/10.1136\/bjsports-2018-100054.","journal-title":"Br J Sports Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01669-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:38:06Z","timestamp":1778650686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-024-01669-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01669-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's note: Readers are alerted that concerns have been raised regarding the reproducibility of the results presented in this article. Further editorial action will be taken if appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clarification","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor\u2019s Note: A Matters Arising article (","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-025-01699-6","URL":"https:\/\/doi.org\/10.1186\/s13195-025-01699-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":") and the Authors' Response (","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-025-01728-4","URL":"https:\/\/doi.org\/10.1186\/s13195-025-01728-4","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":") have now been published.","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required as the study was conducted using de-identified publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}